LHHealthcare · Diagnostics & ResearchThe 18 Wall Street analysts covering Labcorp Holdings, Inc. hold a median 12-month price target of $350 — +10.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 86 of 100 as at 15 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Labcorp Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (96): The share price has been relatively steady.
Accruals (55): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (9): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on LH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +10.0% from it.
Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 Aug 2026 | Piper Sandler | Maintains | Neutral | $300 → $309 |
| 3 Aug 2026 | JP Morgan | Maintains | Overweight | $330 → $360 |
| 31 July 2026 | Barclays | Maintains | Equal-Weight | $290 → $320 |
| 31 July 2026 | Morgan Stanley | Maintains | Overweight | $308 → $338 |
| 31 July 2026 | Truist Securities | Maintains | Buy | $320 → $350 |
| 13 July 2026 | B of A Securities | Maintains | Buy | — |
| 13 July 2026 | B of A Securities | Maintains | Buy | $300 → $320 |
| 13 July 2026 | Baird | Maintains | Outperform | $335 → $338 |
| 13 July 2026 | Baird | Maintains | Outperform | — |
| 8 Apr 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 24 Feb 2026 | Piper Sandler | Maintains | Neutral | — |
| 18 Feb 2026 | Baird | Maintains | Outperform | — |
| 18 Feb 2026 | JP Morgan | Maintains | Overweight | — |
| 6 Feb 2026 | JP Morgan | Maintains | Overweight | — |
| 7 Nov 2025 | JP Morgan | Maintains | Overweight | — |
| 29 Oct 2025 | UBS | Maintains | Buy | — |
| 17 Oct 2025 | Mizuho | Maintains | Outperform | — |
| 17 Oct 2025 | UBS | Maintains | Buy | — |
| 3 Oct 2025 | Evercore ISI Group | Maintains | Outperform | — |
| 2 Oct 2025 | Barclays | Maintains | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LH appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 31% of US stocks
Cheaper than 56% of US stocks
Cheaper than 35% of US stocks
Cheaper than 26% of US stocks
Higher than 41% of US stocks
Higher than 64% of US stocks
Higher than 35% of US stocks
Higher than 68% of US stocks
Higher than 64% of US stocks
Higher than 68% of US stocks
Higher than 79% of US stocks
Higher than 21% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Labcorp Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Labcorp CEO Adam Schechter sold 4,669 shares at $320.37 per share on August 11, 2026, for approximately $1.5 million. The sale reduced his total equity holdings in the company by 4%.
Why it matters — A 4% reduction in the CEO's holdings is a notable insider transaction that a Labcorp shareholder would track for potential signals about executive sentiment.
Zacks Investment Research reports that Labcorp enters late 2026 with stronger growth, improved margins, and raised guidance, though a high valuation and cost risks temper the outlook.
Why it matters — A Labcorp watcher would care because the analysis highlights both positive operational momentum and lingering valuation and cost concerns that shape the stock's near-term risk-reward balance.
Zacks Investment Research highlighted Labcorp Holdings (LH) as a strong momentum stock, referencing its Zacks Style Scores feature, which helps investors identify stocks across value, growth, and momentum categories.
Why it matters — Labcorp watchers may note that the company is being recognized as having strong momentum characteristics in Zacks' stock-ranking framework.
Labcorp announced that the U.S. FDA approved its PGDx elio tissue complete CDx as a companion diagnostic to identify advanced melanoma patients with certain BRAF variants who may benefit from approved BRAF and BRAF/MEK inhibitor therapies. The approval supports access to targeted treatment options for advanced melanoma.
Why it matters — An FDA approval for a new companion diagnostic expands Labcorp's FDA-cleared oncology testing portfolio and its role in precision medicine for advanced melanoma.
Labcorp (LH) shares rose 14% over the past month, driven by stronger earnings and margin gains, while the stock's valuation now sits above its five-year median. The price increase reflects a combination of growth momentum and an increasingly rich valuation.
Why it matters — A LH watcher would care because the stock's rapid climb signals improving financial performance even as its elevated valuation relative to historical levels raises the question of how much growth is already priced in.
The 18 Wall Street analysts covering Labcorp Holdings, Inc. have a median 12-month price target of $350, with estimates ranging from $270 to $385. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 18 analysts covering Labcorp Holdings, Inc., 13 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Labcorp Holdings, Inc. 86 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, Labcorp Holdings, Inc. ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (96 of 100).
No one can know that. What the data says: the median 12-month target from 18 analysts implies +10.0% from the last close, and Ticker Nerd's factor model ranks Labcorp Holdings, Inc. 86 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Labcorp Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $270 to $385 over the next 12 months.
Labcorp Holdings, Inc. returned +18.5% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Labcorp Holdings Inc. is a healthcare diagnostics and laboratory services company that supports physicians, hospitals, pharmaceutical companies, researchers, and patients with clinical testing and scientific insights.
The most recent item we track (The Motley Fool, 12 Aug 2026): "Labcorp CEO Adam Schechter Sells 4,669 Shares for $1.5 Million". Labcorp CEO Adam Schechter sold 4,669 shares at $320.37 per share on August 11, 2026, for approximately $1.5 million. The sale reduced his total equity holdings in the company by 4%.
Labcorp Holdings Inc. is a healthcare diagnostics and laboratory services company that supports physicians, hospitals, pharmaceutical companies, researchers, and patients with clinical testing and scientific insights. Labcorp Holdings Inc. operates through its Diagnostics Laboratories and Biopharma Laboratory Services segments, providing a broad portfolio of routine blood and urine tests as well as specialized services in oncology, genomics, and drug development support. The company maintains an extensive network of patient-service centers and laboratory operations that help deliver testing access, sample processing, and analytical capabilities across the healthcare system. Labcorp Holdings Inc. plays an important role in clinical decision-making, disease detection, and research support by translating laboratory data into information used in patient care and life sciences workflows.
CEO Mr. Adam H. Schechter · 71,000 employees · United States · https://www.labcorp.com